Correction to: Leukemia https://doi.org/10.1038/s41375-021-01125-4, published online 22 January 2021
In Supplementary Table 2, the n numbers for the response-evaluable patients with higher-risk MDS were swapped for the pevonedistat + azacitidine arm and the azacitidine alone arm. Instead of n = 30 and n = 29 as originally published, these have now been corrected to n = 29 for pevonedistat + azacitidine and n = 30 for azacitidine. No changes were required to the response rate percentages as these were calculated using the correct denominators.
The updated files are attached to this correction.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41375-021-01125-4.
Supplementary information
Rights and permissions
About this article
Cite this article
Sekeres, M.A., Watts, J., Radinoff, A. et al. Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia 35, 3637 (2021). https://doi.org/10.1038/s41375-021-01473-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-021-01473-1